Shots: Novartis has received the FDA’s feedback following their review of data from the STRONG study of AVXS-101 (IT) in older patients with SMA. The FDA has recognized the potential […]readmore
Tags : AVXS-101
Shots: The P-I/II STRONG study involves assessing AVXS-101 (IT) in patients with SMA Type 2 who have three copies of the SMN2 gene, and who can sit but cannot stand […]readmore